SIGA Technologies : Management Presentation (May 2025)

Published: 2025-05-09 12:01:04 ET SIGA

Published on 05/09/2025 at 12:01

A Leader in Global Health & Infectious Diseases

1

Contents

SIGA at a Glance

Stellar Revenue Generation

>$1bn of Procurement Contracts from 10+ years Working with Governments

30+ Countries Where Products Have Been Sold

TPOXX

A Foundational Franchise & Trusted Treatment for Smallpox(1)

Strong Expertise Infectious Disease, Health Security, and Government Contracting

We are dedicated to advancing our strategic initiatives, driving shareholder value, and enhancing national health security as we deliver TPOXX to U.S. and global government agencies and progress our clinical programs.

- Diem Nguyen, Chief Executive Officer

Who We Are

SIGA is a public, commercial-stage pharmaceutical company and leader in biodefense and global health security, focused on manufacturing and developing innovative medicines to treat and prevent infectious diseases, with a primary focus on orthopoxviruses. The company is headquartered in New York City, with research and development operations in Corvallis, Oregon.

Development Pipeline

Targeting regulatory submissions for new TPOXX indications, including smallpox

Moving into complementary therapeutic areas

Strategic Priorities

Continue our partnership with the U.S. government

Advance regulatory approvals of TPOXX in new indications and formulations

Cultivate strategic partnerships to expand global access to TPOXX

Leverage capabilities to move into complementary therapeutic areas

Tecovirimat-SIGA is approved by the EMA and MHRA , and TEPOXX is approved by the PMDA, for the treatment of monkeypox, cowpox, smallpox, and complications

from vaccinia virus; TPOXX is approved by the U.S. FDA and Health Canada for the treatment of smallpox. TPOXX is not approved as a treatment for mpox in the U.S. 4

SIGA is a Leader in Global Health Security

Fully Integrated Infectious Disease Capabilities

Experienced senior management team with deep expertise

Fully integrated, U.S.-based operational supply chain

Foundation for Continued Attractive Growth

Leading TPOXX Product Platform

Best-in-Class Financial Performance

Oral TPOXX is approved in the U.S., Canada, Europe, UK, and Japan

Realized ~s650 mm of TPOXX revenue with robust gross margins in 2020 - 2024

Highly profitable company with ~s370 mm in pre-tax operating income in 2020 - 2024

Robust balance sheet and cash flow with minimal CAPEX

and no debt

5

Disclaimer

SIGA Technologies Inc. published this content on May 09, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 09, 2025 at 16:00 UTC.